601 264 6000
South Mississippi's Largest Multi-Specialty Clinic

Hattiesburg Clinic

Memory Center - Research Trials

The Memory Center conducts clinical trials that focus on neurological therapeutics, with Alzheimer’s disease being an area of special interest and expertise. Basic research techniques generate ideas about which medical strategies may be likely to help alleviate symptoms of an illness or disease. Clinical research protocols are then developed in order to test these hypotheses.

Memory Center – Research Trials

Clinical trials are designed to determine if a new treatment will be both safe and effective for patients. In addition, trials will often collect data to determine whether an investigational strategy will have a broader influence on related problems such as activities of daily living, caregiver stress or general quality of life.

Clinical trials in Alzheimer’s disease will usually involve both patients and caregivers. While trial participation is completely voluntary, it is important to recognize the time and effort involved in the successful completion of a clinical trial.

The Memory Center is gratified to be able to offer our community access to potential new treatments for Alzheimer’s. New treatments can only be discovered through the partnership of patient volunteers, research sites, and scientific sponsors. Everyone plays an important role in this investigational process. Every day, we work with hopeful optimism towards more effective therapies, more accurate diagnoses, and eventually a sustainable cure for Alzheimer’s disease.

None of this happens without your help.

CURRENTLY ENROLLING TRIALS

Clarity AD (BAN2401-G000-301) NCT03887455

  • This study will be conducted to evaluate the efficacy of BAN2401 in participants with early Alzheimer’s disease (EAD) by determining the superiority of BAN2401 compared with placebo on the change from baseline in the Clinical Dementia Rating-Sum of Boxes (CDR-SB) at 18 months of treatment in the Core Study. This study will also evaluate the long-term safety and tolerability of BAN2401 in participants with EAD in the Extension Phase and whether the long-term effects of BAN2401 as measured by the CDR-SB at the end of the Core Study is maintained over time in the Extension Phase.
  • For more information please visit clarityadstudy.com

The GAIN Trial (COR388-010) Identifier: NCT03823404

  • This is a randomized, double-blind, placebo-controlled study that will assess the efficacy, safety, and tolerability of 2 dose levels of COR388 in subjects with a clinical diagnosis of mild to moderate AD dementia.
  • For more information, visit www.gaintrial.com

ACTIVE NON-ENROLLING TRIALS

AWARE Study (M15-566) NCT02880956

  • A Phase 2 Multiple Dose, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ABBV-8E12 in Subjects With Early Alzheimer’s Disease
  • The Aware Study is evaluating an investigational medication that targets a protein called tau, which builds-up in the brains of people with Early Alzheimer’s disease.
  • For more information, visit www.theawarestudy.com

elevage (TTP488-305) Identifier: NCT03980730

  • This is a study to evaluate the efficacy and safety of azeliragon in patients with mild Alzheimer’s disease and impaired glucose tolerance. Patients will receive either azeliragon or placebo with a patient’s participation lasting approximately 9 months (in Part 1) or 21 months (in Part 2).

EMBARK (221AD304) NCT04241068

  • Phase 3b Open-Label, Multicenter, Safety Study of BIIB037 (Aducanumab) in Subjects With Alzheimer’s Disease Who Had Previously Participated in the Aducanumab Studies 221AD103, 221AD301, 221AD302 and 221AD205

H8A-US-B004 (GERAS-US) Identifier: NCT02951598

  • The purpose of this study is to learn about health care use, costs, and clinical outcomes over time for amyloid positive participants with early stages of AD in the United States. This study is for research purposes only, and is not intended to treat any medical condition. No study therapy(ies) for AD will be administered

The Memory Center provides patients in south Mississippi with access to leading-edge clinical trials and care for those suffering with Alzheimer’s disease, dementia and other cognitive impairment disorders. By partnering with both academia and industry, the Memory Center is able to integrate research studies into the flow of clinical neurology practice. 

FOR MORE INFORMATION REGARDING CLINICAL TRIAL PARTICIPATION:

Why Participate?

http://www.nih.gov/health/clinicaltrials/whyparticipate.htm

Common Questions

http://www.nih.gov/health/clinicaltrials/basics.htm

Alzheimer’s Research

https://www.nia.nih.gov/alzheimers/clinical-trials

Participating in Alzheimer’s Research

https://www.nia.nih.gov/health/participating-alzheimers-disease-research

Memory Center Logo

CONTACT US

Caregiver Name (if applicable)

Patient Name (if applicable)

Patient Date of Birth (if applicable)

Your Email (required)

Your Phone (required)

Please check the box below:

I agree for a representative from Hattiesburg Clinic Memory Center to contact me.

Your Message

Please do not use this contact form to send any messages requiring urgent attention. For urgent medical matters, contact your doctor’s office or visit the nearest emergency room. This messaging system is monitored only during normal business hours. It is not monitored after hours or on holidays.

DIRECTOR & PRINCIPAL INVESTIGATOR

Ronald L. Schwartz, MD, CPI

Ronald L. Schwartz, MD, CPI

PHONE

(601) 579-5016

ADDRESS

415 South 28th Ave.
Main Clinic – 6th Floor
Hattiesburg, MS 39401
Directions

HOURS

Monday – Friday
8:00 a.m. – 5:00 p.m.

CONNECT THROUGH IRIS